Vericel Q2 revenue $37M, net loss $9M; maintains FY guidance, NexoBrid BLA accepted with PDUFA Jan 2023

Vericel Corp

2022-Q2 EPS reported -$0.34 revenue$73,120,000

Total net revenue $37.0M (MACI $28.6M +8% YoY, Epicel $8.2M, NexoBrid $0.2M); net loss $9.0M ($0.19/sh).
Non-GAAP adjusted EBITDA $2.8M (7% margin); operating cash flow $3.1M; cash & investments $131M, no debt.
FY 2022 guidance reaffirmed: total revenue $178-189M, MACI $132-141M, gross margin ~69%, adj. EBITDA margin ~21%.
NexoBrid BLA resubmission accepted by FDA; PDUFA date Jan 1, 2023.
Entered $150M revolving credit facility with J.P. Morgan-led syndicate; issued inaugural ESG report.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.